These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 18788906)
1. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Li J; Sun W; Wang B; Xiao X; Liu XQ Hum Gene Ther; 2008 Sep; 19(9):958-64. PubMed ID: 18788906 [TBL] [Abstract][Full Text] [Related]
2. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Koo T; Popplewell L; Athanasopoulos T; Dickson G Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945 [TBL] [Abstract][Full Text] [Related]
3. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy. Lai Y; Li D; Yue Y; Duan D Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629 [TBL] [Abstract][Full Text] [Related]
11. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. Gonçalves MA; van Nierop GP; Tijssen MR; Lefesvre P; Knaän-Shanzer S; van der Velde I; van Bekkum DW; Valerio D; de Vries AA J Virol; 2005 Mar; 79(5):3146-62. PubMed ID: 15709034 [TBL] [Abstract][Full Text] [Related]
12. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. Le Hir M; Goyenvalle A; Peccate C; Précigout G; Davies KE; Voit T; Garcia L; Lorain S Mol Ther; 2013 Aug; 21(8):1551-8. PubMed ID: 23752313 [TBL] [Abstract][Full Text] [Related]
14. Trans-splicing adeno-associated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency. Xu Z; Yue Y; Lai Y; Ye C; Qiu J; Pintel DJ; Duan D Hum Gene Ther; 2004 Sep; 15(9):896-905. PubMed ID: 15353044 [TBL] [Abstract][Full Text] [Related]
15. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596 [TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Fabb SA; Wells DJ; Serpente P; Dickson G Hum Mol Genet; 2002 Apr; 11(7):733-41. PubMed ID: 11929846 [TBL] [Abstract][Full Text] [Related]
17. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Peccate C; Mollard A; Le Hir M; Julien L; McClorey G; Jarmin S; Le Heron A; Dickson G; Benkhelifa-Ziyyat S; Piétri-Rouxel F; Wood MJ; Voit T; Lorain S Hum Mol Genet; 2016 Aug; 25(16):3555-3563. PubMed ID: 27378686 [TBL] [Abstract][Full Text] [Related]
18. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713 [TBL] [Abstract][Full Text] [Related]
19. Screening for antisense modulation of dystrophin pre-mRNA splicing. Dickson G; Hill V; Graham IR Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S67-70. PubMed ID: 12206799 [TBL] [Abstract][Full Text] [Related]
20. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy. Athanasopoulos T; Foster H; Foster K; Dickson G Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]